Corbus Announces Restructuring, Cuts Workforce by 54%

Corbus Pharmaceuticals announced a restructuring of its workforce designed to reallocate capital to certain clinical and preclinical programs. The restructuring will result in a reduction of its workforce by 54%.

Corbus will allocate resources towards its lenabasum clinical development program in dermatomyositis (DM) and systemic lupus erythematosus (SLE), and the Company’s pipeline of other novel ECS-targeting drug candidates. The pipeline includes cannabinoid receptor type 1 (CB1) inverse agonists, follow-on cannabinoid receptor type 2 (CB2) agonists, as well as other programs with their own unique mechanism of action in the ECS field. Corbus recorded cash and cash equivalents of approximately $83 million at September 30, 2020.

The Company intends to reduce ongoing expenses and extend its existing cash runway through the following restructuring initiatives and to prioritize its pipeline, which includes:

• Reduce workforce by 54%

• Focusing on those tasks on the critical path for lenabasum in DM and SLE

• Prioritizing its preclinical pipeline based on what the Company believes is its most promising candidates

“I want to thank our employees for their invaluable contributions to Corbus and the commitment they have shown to improving lives of people with rare inflammatory diseases. We believe that reorganizing the business is critical to our success. We will continue to focus our strategy on the potential for lenabasum in serious autoimmune diseases, including through the completion of our Phase 3 clinical trial in DM with an expected data readout in Q4 of next year, and leveraging our preclinical pipeline,” Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, said. “We plan to present the full dataset from the RESOLVE-1 Phase 3 study at upcoming medical conferences and are continuing to analyze the data to better understand potential for further study in systemic sclerosis. The dataset from our Phase 2b cystic fibrosis study is currently being presented at the NACFC 2020 conference, and we are assessing potential next steps in CF.”